However, mutations in CTNNB1 are highly prevalent in hepatocellular carcinoma (24%), sarcoma (44%) and testicular cancer(24%) [29], suggesting that these cancers may potentially have increased sensitivity to RK-33. The gene discussed is CTNNB1; the disease is cancer.